Upadacitinib
- Generic Name
- Upadacitinib
- Brand Names
- Rinvoq
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19F3N6O
- CAS Number
- 1310726-60-3
- Unique Ingredient Identifier
- 4RA0KN46E0
- Background
Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, auto...
- Indication
Upadacitinib is indicated for the treatment of moderately to severely active rheumatoid arthritis or active psoriatic arthritis in adult patients who have had an inadequate response or intolerance to one or more disease-modifying anti-rheumatic drugs (DMARDs), such as TNF blockers. In Europe, upadacitinib may be used as monotherapy or in combination with met...
- Associated Conditions
- Ankylosing Spondylitis (AS), Moderately to Severely Active Rheumatoid Arthritis, Moderately to Severely Active Ulcerative Colitis, Severe Atopic Dermatitis, Active Ankylosing spondylitis, Active Non-radiographic Axial Spondyloarthritis, Active Psoriatic arthritis, Moderate, active Crohn´s Disease, Moderate, refractory Atopic dermatitis, Refractory, severe Atopic Dermatitis, Severe, active Crohn´s Disease
- Associated Therapies
- -
Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 98
- Registration Number
- NCT06701331
- Locations
- 🇯🇵
Medical corporation Jun Dermatology Clinic /ID# 269953, Osaka-shi, Osaka, Japan
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Target Recruit Count
- 150
- Registration Number
- NCT06573593
- Locations
- 🇨🇳
Second Affiliated Hospital, School of Medicine, Zhejiang University, China, Hangzhou, Zhejiang, China
Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)
- Conditions
- Interventions
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Universidade do Porto
- Target Recruit Count
- 150
- Registration Number
- NCT06498167
- Locations
- 🇵🇹
Unidade Local de Saúde de São João, E.P.E., Porto, Portugal
🇵🇹Unidade Local de Saúde de Santo António, E.P.E., Porto, Portugal
🇵🇹Unidade Local de Saúde de Gaia/Espinho, E.P.E., Porto, Portugal
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 675
- Registration Number
- NCT06461897
- Locations
- 🇺🇸
Medical University of South Carolina /ID# 265113, Charleston, South Carolina, United States
🇬🇧Chelsea and Westminster Hospital /ID# 266389, London, Greater London, United Kingdom
🇺🇸Integrative Skin Science and Research /ID# 265108, Sacramento, California, United States
A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 112
- Registration Number
- NCT06390722
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 110
- Registration Number
- NCT06332534
- Locations
- 🇪🇸
Hospital Universitario Virgen del Rocio /ID# 262712, Sevilla, Spain
🇺🇸OSF St. Francis Medical Center /ID# 262192, Peoria, Illinois, United States
🇺🇸Indiana University Health Riley Hospital for Children /ID# 262215, Indianapolis, Indiana, United States
Efficacy and Safety Analysis of Upadacitinib in Inflammatory Bowel Disease
- Conditions
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2024-02-23
- Target Recruit Count
- 81
- Registration Number
- NCT06274996
- Locations
- 🇨🇳
the Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 396
- Registration Number
- NCT06227910
Response to Upadacitinib of Enthesitis Evaluated by Ultrasound in Patients With Psoriatic Arthritis
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2023-11-29
- Target Recruit Count
- 19
- Registration Number
- NCT06144567
- Locations
- 🇪🇸
Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
- Conditions
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 614
- Registration Number
- NCT06118411
- Locations
- 🇺🇸
Joseph Raoof Md,Inc /Id# 260055, Encino, California, United States
🇺🇸Alliance Dermatology and Mohs Center /ID# 259926, Phoenix, Arizona, United States
🇺🇸University of California Irvine /ID# 260080, Irvine, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.